MX2023001963A - Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. - Google Patents

Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.

Info

Publication number
MX2023001963A
MX2023001963A MX2023001963A MX2023001963A MX2023001963A MX 2023001963 A MX2023001963 A MX 2023001963A MX 2023001963 A MX2023001963 A MX 2023001963A MX 2023001963 A MX2023001963 A MX 2023001963A MX 2023001963 A MX2023001963 A MX 2023001963A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions containing
hypertonic pharmaceutical
platinum chemoprotectant
chemoprotectant agent
Prior art date
Application number
MX2023001963A
Other languages
English (en)
Inventor
John Lee
Qi- Ying HU
Fuxin Shi
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of MX2023001963A publication Critical patent/MX2023001963A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas hipertónicas. Las composiciones farmacéuticas hipertónicas contienen un agente quimi7oprotector antiplatino y un agente gelificante. También se describen métodos de uso médico de las composiciones farmacéuticas hipertónicas.
MX2023001963A 2018-02-09 2020-08-07 Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. MX2023001963A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862628824P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
MX2023001963A true MX2023001963A (es) 2023-02-23

Family

ID=67549759

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008323A MX2020008323A (es) 2018-02-09 2019-02-08 Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.
MX2023001963A MX2023001963A (es) 2018-02-09 2020-08-07 Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020008323A MX2020008323A (es) 2018-02-09 2019-02-08 Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.

Country Status (12)

Country Link
US (3) US10709732B2 (es)
EP (1) EP3749309A4 (es)
JP (2) JP7492917B2 (es)
KR (1) KR20200129107A (es)
CN (1) CN112020359A (es)
AU (1) AU2019218232A1 (es)
BR (1) BR112020016059A2 (es)
CA (1) CA3090783A1 (es)
IL (1) IL276569B2 (es)
MX (2) MX2020008323A (es)
SG (1) SG11202007595WA (es)
WO (1) WO2019157370A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
US20220296637A1 (en) * 2019-06-19 2022-09-22 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss
EP4051287A4 (en) * 2019-10-30 2023-12-27 Otonomy, Inc. EAR FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY
JP2023515072A (ja) 2020-02-21 2023-04-12 アコーオス インコーポレイテッド ヒト対象において非加齢関連聴力障害を処置するための組成物および方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6497902B1 (en) 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
CA2406081C (en) 2000-04-26 2009-12-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
BRPI0515973B8 (pt) 2004-10-12 2021-07-27 Fmc Biopolymer As kit para produzir um gel de alginato, composição para preparar um gel e uso
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
WO2008056822A1 (en) 2006-11-09 2008-05-15 Takeda Pharmaceutical Company Limited Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
CA2721927C (en) * 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
HUE035519T2 (en) 2009-07-08 2018-05-02 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical composition
US20130045957A1 (en) 2011-02-18 2013-02-21 Otonomy, Inc. Prevention of and Recovery from Drug-Induced Ototoxicity
US10130514B2 (en) 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
WO2016191468A1 (en) * 2015-05-28 2016-12-01 Baylor College Of Medicine Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels
MX2018001571A (es) 2015-08-05 2018-09-06 Childrens Medical Center Composiciones con potenciadores de permeacion para suministro de farmacos.
US20190038756A1 (en) 2016-02-10 2019-02-07 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019118330A1 (en) 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
US10946443B2 (en) 2018-01-08 2021-03-16 Hamilton Sundstrand Corporation Removal of unfused powder from an additive-manufactured part using piezoelectric transducers
CN115869389A (zh) 2018-01-09 2023-03-31 奥德纳米有限公司 生长因子耳用制剂
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
WO2019210107A1 (en) 2018-04-25 2019-10-31 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
IT201800006566A1 (it) 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
WO2020009954A1 (en) 2018-07-03 2020-01-09 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
US20220296637A1 (en) 2019-06-19 2022-09-22 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Also Published As

Publication number Publication date
IL276569B2 (en) 2023-06-01
MX2020008323A (es) 2020-10-14
EP3749309A4 (en) 2021-12-08
AU2019218232A1 (en) 2020-09-24
US11071751B2 (en) 2021-07-27
JP7492917B2 (ja) 2024-05-30
WO2019157370A1 (en) 2019-08-15
US20190336524A1 (en) 2019-11-07
BR112020016059A2 (pt) 2020-12-08
EP3749309A1 (en) 2020-12-16
JP2024098070A (ja) 2024-07-19
US11857567B2 (en) 2024-01-02
US20200338119A1 (en) 2020-10-29
JP2021513558A (ja) 2021-05-27
CN112020359A (zh) 2020-12-01
SG11202007595WA (en) 2020-09-29
CA3090783A1 (en) 2019-08-15
IL276569A (en) 2020-09-30
US10709732B2 (en) 2020-07-14
KR20200129107A (ko) 2020-11-17
US20210308176A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2019012978A (es) Composiciones para el cuidado bucal y metodos para utilizar las composiciones.
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2019014041A (es) Inhibidores pirazolicos de magl.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
PH12019502548A1 (en) Pyrazole magl inhibitors
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
ZA202001756B (en) Oral care compositions
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MY172113A (en) A pharmaceutical composition for neuropathic pain
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2018001989A (es) Formulaciones farmaceuticas.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.